GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.
GLP-1 drugs show promise in animal models of inherited kidney disease, suggesting a new avenue to slow progression in high-risk patients.
ADPKD is the most common monogenic kidney disease and remains therapeutically limited to tolvaptan, with significant progression heterogeneity suggesting additional disease biology. This review makes the translational case for GLP-1 receptor agonist investigation in metabolically high-risk ADPKD patients, where semaglutide has shown benefit in Pkd1 animal models.
What the study was
- Study design
- review
- Population
- ADPKD patients, particularly metabolically at-risk phenotype
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Transl Res
Why it surfaced
Standard: GLP-1 agonists in a rare kidney disease represent a novel indication with emerging mechanistic rationale; ADPKD has high unmet need beyond existing approved therapy; review design without clinical trial data limits pipeline priority to STANDARD; score 7 per conservative cap for review without human RCT evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.